An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes.
Ontology highlight
ABSTRACT: Guidelines have increasingly stressed the concept that adequate glycemic control is required to prevent or decrease the macro- and microvascular complications of type 2 diabetes mellitus (T2DM). PPAR-gamma agonists ("glitazones") are no longer prioritized due to their effects on heart failure. However, the association between these drugs and innovative therapies could be a valuable tool to attenuate the risk factors of the metabolic syndrome. Glitazones are used for the treatment of diabetes and associated comorbidities. There is substantial scientific evidence demonstrating the effect of glitazones at a cardiometabolic level, as well as on hematological and neurological pathologies that point to their usefulness. The use of glitazones has always been controversial both for the type of pat
SUBMITTER: Giglio RV
PROVIDER: S-EPMC9609741 | biostudies-literature | 2022 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA